Search Results

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

• Authors : Sio Gene Therapies

• Source: A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisLewis CJ, D'Souza P,

Record details

Administration of Donor T Cells With the Caspase-9 Suicide Gene (DOTTI)

• Authors : The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine; Malcolm Brenner, Director/Professor, Center for Cell and Gene Therapy

• Source: Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide GeneZhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT,

Record details

Gene Editing as a Therapeutic Approach for Rett Syndrome (MECPer-3D)

• Authors : Ilaria Meloni, Associate professor

• Source: Personalized MECP2 Gene Therapy Using CRISPR/Cas9 Technology Coupled to AAV-mediated Delivery in 3D Cell Culture and KI Mice

Record details

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene (CASPALLO)

• Authors : The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine; Malcolm Brenner, Principal Investigator

• Source: CASPALLO: A Phase I Study Evaluating the Use of Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation

Record details

A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells (CHESAT)

• Authors : Center for Cell and Gene Therapy, Baylor College of Medicine; Andras Heczey, Assistant Professor

• Source: A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell

Record details

Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

• Source: Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

Record details

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

• Authors : National Cancer Institute (NCI)

• Source: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation

Record details

Liver Biopsy Following Gene Therapy For Hemophilia

• Authors : Methodist University Hospital

• Source: Liver Biopsy Following Gene Therapy For Hemophilia

Record details

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

• Authors : ORA, Inc.

• Source: A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Record details

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

• Source: Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With

Record details